Bioavailability of Sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China
Egner PA, Chen JG, Wang JB, Wu Y, Sun Y, Lu JH, Zhu J, Zhang YH, Chen YS, Friesen MD, Jacobson LP, Muñoz A, Ng D, Qian GS, Zhu YR, Chen TY, Botting NP, Zhang Q, Fahey JW, Talalay P, Groopman JD, Kensler TW
Cancer prevention research (Philadelphia, Pa.) · 162 citas
Cómo se estudió
- Diseño
- Ensayo clínico controlado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Sin resultado de salud
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Johns Hopkins University
- Gobierno
- National Cancer Institute
- Gobierno
- National Institute of Environmental Health Sciences
- Gobierno
- NIEHS NIH HHS
- Gobierno
- NCI NIH HHS
- Subvenciones
- National Cancer Institute (R01 CA93780); National Institute of Environmental Health Sciences (P30 ES 003819); National Institute of Environmental Health Sciences (ES003819); National Institute of Environmental Health Sciences (P01 ES006052); National Cancer Institute (R01 CA093780)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2011-03-01 · Cancer Prev Res (Phila) · vol. 4 · número 3 · págs. 384–395
- Editorial
- American Association for Cancer Research
- Citado
- 207 citas · más que el 98% de estudios similares · 6.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 47 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Bioactive Compounds and Antitumor Agents
- Palabras clave
- Sulforaphane, Glucoraphanin, Bioavailability, Glucosinolate, Myrosinase, Dosing, Tolerability, Raphanus, Food science, Excretion, Brassica, Chemistry, Animal science, Medicine, Pharmacology, Toxicology, Adverse effect, Biochemistry, Botany, Biology
- MeSH
- humans, brassica, raphanus, oximes, thiocyanates, imidoesters, isothiocyanates, sulfhydryl compounds, sulfoxides, glycoside hydrolases, glucosinolates, anticarcinogenic agents, treatment outcome, cross-over studies, reproducibility of results, signal transduction, biological availability, genotype, beverages, adult, aged, middle aged, china, female, male
22 autores
- Patricia A. Egner🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Jianguo Chen🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Jin Bing Wang🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Yan Wu🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Yan Sun🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Jian Lu🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Jian Zhu🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Yong Hui Zhang🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Yong Sheng Chen🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Marlin D. Friesen🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Lisa P. Jacobson🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Álvaro Muñoz🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Derek K. Ng🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Geng Qian🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Yuan Rong Zhu🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Tao Yang Chen🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Nigel P. Botting🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Qingzhi Zhang🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Jed W. Fahey🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Paul Talalay🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- John D. Groopman🇺🇸🇬🇧🇨🇳Johns Hopkins University; University of St Andrews; University of Pittsburgh; Qidong Liver Cancer Prevention Research
- Thomas W. Kensler🇺🇸🇬🇧 · autor de correspondenciaJohns Hopkins University; University of St Andrews; University of Pittsburgh
Resumen
El texto original del estudio, en el idioma en que se publicó.
One of several challenges in design of clinical chemoprevention trials is the selection of the dose, formulation, and dose schedule of the intervention agent. Therefore, a cross-over clinical trial was undertaken to compare the bioavailability and tolerability of sulforaphane from two of broccoli sprout-derived beverages: one glucoraphanin-rich (GRR) and the other sulforaphane-rich (SFR). Sulforaphane was generated from glucoraphanin contained in GRR by gut microflora or formed by treatment of GRR with myrosinase from daikon (Raphanus sativus) sprouts to provide SFR. Fifty healthy, eligible participants were requested to refrain from crucifer consumption and randomized into two treatment arms. The study design was as follows: 5-day run-in period, 7-day administration of beverages, 5-day washout period, and 7-day administration of the opposite intervention. Isotope dilution mass spectrometry was used to measure levels of glucoraphanin, sulforaphane, and sulforaphane thiol conjugates in urine samples collected daily throughout the study. Bioavailability, as measured by urinary excretion of sulforaphane and its metabolites (in approximately 12-hour collections after dosing), was substantially greater with the SFR (mean = 70%) than with GRR (mean = 5%) beverages. Interindividual variability in excretion was considerably lower with SFR than with GRR beverage. Elimination rates were considerably slower with GRR, allowing for achievement of steady-state dosing as opposed to bolus dosing with SFR. Optimal dosing formulations in future studies should consider blends of sulforaphane and glucoraphanin as SFR and GRR mixtures to achieve peak concentrations for activation of some targets and prolonged inhibition of others implicated in the protective actions of sulforaphane. Cancer Prev Res; 4(3); 384-95. ©2011 AACR.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.